Nicholas G Bacopoulos

US Patent:

20070190022, Aug 16, 2007

Filed:

Aug 12, 2004

Appl. No.:

10/567953

Inventors:

Nicholas Bacopoulos - Stonington CT, US
Judy Chiao - Berkeley Heights NJ, US
Paul Marks - Washington CT, US
Thomas Miller - Brookline MA, US
Carolyn Paradise - Cortland Manor NY, US
Victoria Richon - Wellesley MA, US
Richard Rifkind - New York NY, US

International Classification:

A61K 38/20
A61K 38/19
A61K 38/09
A61K 31/7072
A61K 31/57
A61K 31/522
A61K 31/19

US Classification:

424085100, 514015000, 424085200, 424155100, 514575000, 514049000, 514251000, 514263310, 424094630, 514269000, 514254070, 514102000, 514171000

Abstract:

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

US Patent:

20080227862, Sep 18, 2008

Filed:

Oct 30, 2007

Appl. No.:

11/980994

Inventors:

Victoria M. Richon - Wellesley MA, US
Judy H. Chiao - Berkeley Heights NJ, US
Thomas A. Miller - Brookline MA, US
Nicholas G. Bacopoulos - Stonington CT, US
Carolyn M. Paradise - Cortland Manor NY, US

International Classification:

A61K 31/167
A61P 19/00

US Classification:

514616

Abstract:

The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

US Patent:

20100273732, Oct 28, 2010

Filed:

Jul 2, 2010

Appl. No.:

12/829740

Inventors:

Nicholas G. Bacopoulos - Stonington CT, US
Judy H. Chiao - Berkeley Heights NJ, US
Paul A. Marks - Washington CT, US
Thomas A. Miller - Brookline MA, US
Carolyn M. Paradise - Cortland Manor NY, US
Victoria M. Richon - Wellesley MA, US
Richard A. Rifkind - New York NY, US

International Classification:

A61K 31/7068
A61P 35/02
A61P 35/00

US Classification:

514 49

Abstract:

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

US Patent:

51303388, Jul 14, 1992

Filed:

Feb 28, 1991

Appl. No.:

7/663073

Inventors:

Nicholas G. Bacopoulos - Stonington CT
Peter A. Blick - Los Gatos CA
B. Kenneth Koe - Ferry CT
Evan R. Norris - Chappaqua NY

Assignee:

Pfizer Inc. - New York NY

International Classification:

H61K 31135

US Classification:

514646

Abstract:

A method of treating a chemical dependency in a mammal, comprising administering to a mammal in need of such treatment an amount of the compound (1S-cis)-4-(3, 4-dichlorophenyl)-1,2,3,4-tetraahydro-N-methyl-1-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in reducing or alleviating such dependency.